CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation from the US Food and Drug Administration (FDA) for its drug candidate Halneuron, which contains tetrodotoxin, for the treatment of chemotherapy-induced neuropathic pain (CINP).
Halneuron is an innovative injectable form of tetrodotoxin, a naturally occurring small molecule known for its ability to block voltage-gated sodium channels on neurons. This action effectively prevents the initiation and conduction of nerve impulses in the peripheral nervous system that are associated with pain. The drug is currently under a Phase IIb study for CINP and is anticipated to offer a novel alternative to traditional anesthetics and opioid analgesics, potentially providing a safer and non-addictive option for pain management.- Flcube.com
